I’ve said before that I think combo approval is effectively mono approval (since combo patients will have no reason not to drop the rest of their regimen). By the same token, I think approval for one cancer indication is effectively approval for them all. Indeed, I don’t think it matters what we’re ultimately approved for — once Leronlimab is on the market and word gets out about what it can do, it’ll be a feeding frenzy.